Efficacy and Safety of Sofosbuvir-based Regimens in Hepatitis C Patients With Decompensated Cirrhosis: A Systematic Review and Meta-analysis.
Wenyan ZhangJing ZhangShan TangYali LiuXiaofei DuLixia QiuMenglu LiuHaibin YuCalvin Qian PanPublished in: Journal of clinical and translational hepatology (2022)
The analysis found that 12 weeks of SOF/velpatasvir without ribavirin is the preferred therapy, with a significantly higher SVR compared with other SOF-based regimens in decompensated HCV patients.